Blockade of ATP-Sensitive Potassium Channels Prevents Myocardial Preconditioning in Dogs

• Published in: Circulation research 1992-02, Vol.70 (2), p.223-233
• Main Authors: Gross, Garrett J, Auchampach, John A
• Format: Article
• Language: English
• Subjects: Adenosine Triphosphate - pharmacology; Animals; Biological and medical sciences; Blood Glucose - analysis; Coronary Circulation; Coronary Disease - metabolism; Coronary Disease - physiopathology; Dogs; Female; Fundamental and applied biological sciences. Psychology; Glyburide - pharmacology; Heart; Heart - drug effects; Heart - physiopathology; Hemodynamics; Male; Myocardial Infarction - pathology; Myocardium - metabolism; Peroxidase - metabolism; Potassium Channels - drug effects; Potassium Channels - physiology; Vertebrates: cardiovascular system
• ISSN: 0009-7330; 1524-4571
• DOI: 10.1161/01.res.70.2.223

Single or multiple brief periods of ischemia (preconditioning) have been shown to protect the myocardium from infarction after a subsequent more prolonged ischemic insult. To test the hypothesis that preconditioning is the result of opening ATP-sensitive potassium (KATP) channels, a selective KATP channel antagonist, glibenclamide, was administered before or immediately after preconditioning in barbital-anesthetized open-chest dogs subjected to 60 minutes of left circumflex coronary artery (LCX) occlusion followed by 5 hours of reperfusion. Preconditioning was elicited by 5 minutes of LCX occlusion followed by 10 minutes of reperfusion before the 60-minute occlusion period. Glibenclamide (0.3 mg/kg i.v.) or vehicle was given 10 minutes before the initial ischemic insult in each of four groups. In a fifth group, glibenclamide was administered immediately after preconditioning. In a final series (group 6), a selective potassium channel opener, RP 52891 (10 μ/kg bolus and 0.1 μg/mg/min i.v.) was started 10 minutes before occlusion and continued throughout reperfusion. Transmural myocardial blood flow was measured at 30 minutes of occlusion, and infarct size was determined by triphenyltetrazolium staining and expressed as a percent of the area at risk. There were no significant differences in hemodynamics, collateral blood flow, or area at risk between groups. The ratio of infarct size to area at risk in the control group (28±6%) was not different from the group pretreated with glibenclamide in the absence of preconditioning (31±6%). Preconditioning produced a marked reduction (p